window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

FDA

  • Central Nervous System,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics

    Celon Pharma receives FDA clearance for Phase 3 trial of CPL’36 in schizophrenia

    Celon Pharma S.A. has received FDA clearance to advance its [...]

    October 8, 2025
  • CDMOs & Manufacturing,Pharmaceuticals and therapeutics,Regulatory Affairs

    Symbiosis expands quality leadership with new qualified person appointment

    Symbiosis Pharmaceutical Services has appointed Wendy Cook as a qualified [...]

    September 14, 2025
  • Clinical Development,Clinical Trials,Oncology,Pharmaceuticals and therapeutics,Rare Diseases,Regulatory Affairs

    FDA and Telix agree resubmission plan for Pixclara glioma imaging agent

    Telix Pharmaceuticals has reached agreement with the US Food and [...]

    September 14, 2025
  • Clinical Trials,Data Management,Real world evidence,Regulatory Affairs

    Clinical trials: TransCelerate and FDA explore pragmatic trial designs to broaden patient access

    TransCelerate BioPharma and the US Food and Drug Administration (FDA) [...]

    August 20, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Development,Regulatory Affairs,Supply Chain & Logistics

    Symbiosis completes 1,000th batch of sterile injectable drug product

    Contract manufacturer Symbiosis Pharmaceutical Services has announced the completion of [...]

    July 31, 2025
  • Clinical Development,Drug Development,Regulatory Affairs,Research & Development,Technology and platforms

    FDA’s phase-out of mandatory animal testing: Certara’s Patrick Smith on biosimulation and the future of drug development

    The US Food and Drug Administration’s (FDA) decision to phase [...]

    July 22, 2025
  • Clinical Trials,Drug Development,Rare Diseases

    Cidara’s long-acting antiviral shows promise in Phase 2b flu prevention trial

    Cidara Therapeutics’ investigational long-acting antiviral, CD388, has achieved statistically significant [...]

    July 17, 2025
  • Cell & Gene Therapy,Clinical Development,Regulatory Affairs

    Nanoscope Therapeutics begins FDA submission for gene-agnostic therapy to treat retinitis pigmentosa

    Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]

    July 15, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Clinical Trials,Regulatory Affairs

    FDA shifts drug testing paradigm with plan to replace animal studies in monoclonal antibody development

    Regulators back AI and organ-on-a-chip technologies to modernize safety evaluation [...]

    June 24, 2025
  • Clinical Trials,Rare Diseases,Regulatory Affairs,Technology and platforms

    Can remote blood collection reinvent trial access? Tasso’s CTO explains how it can do just that

    Tasso is a healthcare technology company pioneering remote, patient-centric solutions [...]

    June 23, 2025
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Symbiosis expands QC capabilities with new 30°C stability chamber
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Manufacturing, Pharmaceuticals and therapeutics
  • Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed
    Categories: Clinical Trials, Immunology, Oncology, Research & Development
  • Chemify founder publishes three papers on programmable chemistry and automated drug discovery
    Categories: Artificial Intelligence, Drug discovery, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top